Quick answer: Iron deficiency anemia affects over 1.2 billion people globally and is the world’s most common nutritional deficiency — yet serum ferritin below 30 ng/mL (functional iron deficiency without frank anemia) is present in 20–40% of premenopausal women and causes fatigue, hair loss, impaired cognition, and exercise intolerance that resolves completely with repletion. Functional hematology targets the root causes of iron deficiency, B12/folate depletion, and anemia of inflammation as reversible upstream pathology rather than treating the lab value alone.
Why Functional Hematology Goes Beyond the CBC
The complete blood count (CBC) identifies frank anemia (hemoglobin <12 g/dL in women, <13 g/dL in men) but misses the far more prevalent functional iron deficiency — a state where tissue iron stores are insufficient for optimal cellular function despite hemoglobin that remains within the normal reference range. The conventional laboratory ferritin reference range (>12 ng/mL) defines deficiency at a level where symptoms have been present for months and tissue depletion is advanced. Functional medicine uses an optimal ferritin range of 50–100 ng/mL for women and 70–150 ng/mL for men — levels at which iron-dependent enzymes, thyroid hormone conversion, and mitochondrial function are fully supported.
Similarly, B12 deficiency is systematically underdiagnosed when serum B12 is used as the sole marker: functional B12 deficiency — evidenced by elevated methylmalonic acid (MMA) and homocysteine — commonly occurs at serum B12 levels of 200–400 pg/mL that fall within the conventional “normal” range. The consequences — subacute combined degeneration, megaloblastic anemia, peripheral neuropathy, cognitive decline, and elevated cardiovascular risk from homocysteine accumulation — are preventable with early identification and treatment.
Iron Deficiency: Root Causes Beyond Dietary Insufficiency
Iron deficiency anemia is classified by conventional medicine as: dietary insufficiency, blood loss (menstrual, GI), or malabsorption. Functional hematology identifies additional root causes that are frequently missed: H. pylori gastric infection (reduces iron absorption via competitive iron binding and gastric acid reduction), celiac disease (duodenal villous atrophy impairs ferrous iron absorption), SIBO (small intestinal bacterial overgrowth consumes iron and produces inflammatory cytokines that upregulate hepcidin), and chronic inflammation itself (elevated IL-6 induces hepcidin, which blocks intestinal iron absorption and reticuloendothelial iron recycling).
Hepcidin: The Master Iron Regulator
Hepcidin — a 25-amino acid peptide produced by the liver — is the master regulator of systemic iron homeostasis. Hepcidin binds ferroportin on duodenal enterocytes and macrophages, causing its internalization and degradation — blocking iron export from intestinal cells into the bloodstream and preventing release of recycled iron from macrophages. High hepcidin (induced by IL-6, LPS, and BMP6 in iron-replete states) reduces serum iron; low hepcidin allows iron absorption to proceed.
In anemia of chronic inflammation (ACI) — formerly called anemia of chronic disease — chronically elevated IL-6 (from rheumatoid arthritis, IBD, chronic infection, obesity, NAFLD) sustains high hepcidin, locking iron in macrophage storage (ferritin high) while serum iron and transferrin saturation are low. The key diagnostic distinction from true iron deficiency: ACI shows normal or elevated ferritin, low TIBC, and low transferrin saturation. Treating the underlying inflammatory driver — not iron supplementation — is the correct functional approach to ACI.
Iron Repletion: Form, Absorption, and Optimization
Ferrous iron (Fe²⁺) is absorbed in the duodenum via DMT1 transporter; ferric iron (Fe³⁺, most common dietary form) requires gastric acid-mediated reduction to ferrous form. Proton pump inhibitors — used chronically by 15% of Americans — dramatically impair iron absorption by raising gastric pH. Oral iron forms: ferrous bisglycinate (glycinate chelate) achieves 90% higher absorption versus ferrous sulfate with 10× fewer GI side effects (Layrisse 2000, Journal of Nutrition) — making it the preferred oral repletion form. Iron taken with vitamin C (250–500 mg) converts ferric to ferrous iron and increases absorption 2–3-fold; taken with calcium, tea (tannins), or coffee reduces absorption by 40–60%.
Alternate-day dosing — every other day rather than daily — produces higher total absorption than daily dosing in recent research by Moretti et al. (2015, Blood): daily iron supplementation provokes a substantial post-dose hepcidin rise that blocks absorption of the next dose; alternate-day dosing allows hepcidin to clear before the next dose, achieving 30% higher fractional absorption per dose. This counterintuitive finding has significant implications for iron repletion efficiency.
Vitamin B12 Deficiency: The Underdiagnosed Epidemic
Vitamin B12 deficiency affects an estimated 6% of adults under 60 and 20% of adults over 60, yet remains systematically underdiagnosed due to inadequate reference ranges and reliance on serum B12 alone. B12 is required for two metabolic functions: methionine synthase (converting homocysteine to methionine, with methylfolate as cofactor) and methylmalonyl-CoA mutase (converting methylmalonyl-CoA to succinyl-CoA for the TCA cycle). Deficiency in either pathway produces distinct consequences: elevated homocysteine (cardiovascular risk, cognitive decline, neural tube defects) and elevated methylmalonic acid (neurological dysfunction, peripheral neuropathy, subacute combined degeneration of the spinal cord).
Metformin and B12 Depletion: The Most Important Drug-Nutrient Interaction
Metformin — prescribed to 120 million people globally for type 2 diabetes — blocks ileal B12 absorption via calcium-dependent competitive inhibition of the cubilin receptor. De Jager et al. (2010, BMJ) demonstrated that metformin use for 4+ years reduced B12 by 19%, with 11.9% of long-term users developing frank deficiency. The ADA guidelines now recommend annual B12 monitoring in metformin users — yet this is inconsistently implemented, leaving millions of patients developing neurological complications attributable to an easily preventable drug-nutrient interaction. Methylcobalamin 1,000 mcg/day sublingually bypasses the ileal absorption defect (sublingual delivery achieves systemic levels via buccal absorption independent of intrinsic factor or ileal uptake).
Optimal B12 Testing: MMA and Homocysteine
Serum B12 >200 pg/mL is conventionally “normal” — yet functional deficiency is documented with MMA and homocysteine at levels up to 400 pg/mL. The functional assessment includes: serum B12 (screening), urine or serum MMA (methylmalonyl-CoA mutase functional marker — elevated when intracellular B12 is insufficient for enzymatic function), and plasma homocysteine (methionine synthase functional marker — elevated with B12 deficiency, folate deficiency, or MTHFR polymorphism). Optimal homocysteine: <8 µmol/L; functional cutoff for intervention at >10 µmol/L; elevated cardiovascular risk documented at >15 µmol/L (Wald 2002, BMJ meta-analysis: homocysteine >15 associated with 3× ischemic heart disease risk).
Folate, MTHFR, and Methylation Pathway Disorders
Folate (vitamin B9) functions as a one-carbon carrier in the methylene-THF cycle, providing methyl groups for thymidylate synthesis (DNA replication), purine synthesis, and homocysteine remethylation to methionine. MTHFR (methylenetetrahydrofolate reductase) is the rate-limiting enzyme converting 5,10-methyleneTHF to 5-methylTHF (the active methyl donor form). MTHFR C677T polymorphism — present in 10–15% of the population in homozygous form — reduces enzyme activity by 30–70%, impairing methyl group production and elevating homocysteine even with adequate dietary folate intake.
The clinical consequence: MTHFR homozygosity increases risk of neural tube defects (15× in folate-deficient mothers), cardiovascular disease, recurrent pregnancy loss, depression, and treatment-resistant psychiatric conditions. The critical intervention: L-methylfolate (5-MTHF) — the pre-converted active form — bypasses the MTHFR enzyme deficiency, delivering methyl groups directly without requiring enzymatic conversion. Conventional folic acid (the synthetic oxidized form) requires four enzymatic steps for conversion to 5-MTHF; in MTHFR-compromised individuals, this conversion is rate-limited. Methylfolate 400–1,000 mcg/day (or 7.5–15 mg/day for psychiatric indications per Stahl’s prescriber guidelines) is the evidence-based supplement form for MTHFR carriers.
Anemia of Chronic Inflammation: Resolving the Root Cause
Anemia of chronic inflammation (ACI) — mild normocytic, normochromic anemia with elevated ferritin, low serum iron, low transferrin saturation, and normal or low TIBC — represents the body’s adaptive response to chronic infection or inflammation: by sequestering iron in macrophages (via hepcidin-ferroportin axis), the body denies iron to potentially iron-dependent pathogens. The challenge is that persistent inflammation from non-infectious conditions (rheumatoid arthritis, IBD, obesity, NAFLD, hypothyroidism) produces identical hepcidin-driven iron restriction — producing functional anemia that does not respond to iron supplementation.
Functional identification of ACI root causes includes: hsCRP and IL-6 (inflammatory drivers of hepcidin), anti-TPO and TSH (hypothyroidism — independent cause of macrocytic anemia), anti-tTG IgA (celiac disease), H. pylori IgG antibody, SIBO breath test, erythrocyte sedimentation rate, and ANA panel (autoimmune inflammatory source). Reduction of the underlying inflammatory driver — anti-inflammatory dietary pattern, treatment of H. pylori, celiac gluten elimination, SIBO eradication, hypothyroid correction — normalizes hepcidin and allows iron absorption and mobilization to resume. This approach outperforms iron supplementation in ACI, which inefficiently supplements iron that cannot be absorbed due to elevated hepcidin.
Hemoglobin Optimization: Nutrients Beyond Iron and B12
Hemoglobin synthesis requires iron (for heme formation), B12 and folate (for red blood cell DNA synthesis and maturation), vitamin B6 (pyridoxal-5-phosphate, required for ALA synthase — the rate-limiting enzyme of heme synthesis), copper (for ceruloplasmin-mediated iron oxidation and ferroxidase activity), and vitamin A (for iron mobilization from storage — vitamin A deficiency impairs erythropoiesis and produces a distinctive hypochromic anemia unresponsive to iron alone). Zinc deficiency impairs erythrocyte superoxide dismutase function and RBC lifespan. Optimizing all cofactors required for hemoglobin synthesis — not just iron — is the functional approach to refractory anemia.
Thiamine (vitamin B1) is required for erythrocyte transketolase activity in the hexose monophosphate shunt — the primary pathway protecting red blood cells from oxidative hemolysis. B1 deficiency produces a distinct hemolytic anemia in severe cases. More commonly, riboflavin (B2) deficiency impairs erythrocyte glutathione reductase (the primary RBC antioxidant enzyme), reducing RBC lifespan and contributing to normo- or mildly macrocytic anemia that resolves dramatically with riboflavin repletion. Comprehensive B-vitamin status assessment — not just B12 — provides a complete hemoglobin optimization picture.
Functional Hematology Testing Panel
A comprehensive functional hematology workup includes: CBC with differential, reticulocyte count (identifies active vs. suppressed erythropoiesis), serum ferritin, serum iron, TIBC, transferrin saturation (iron stores and utilization), serum B12, RBC folate (better reflects tissue folate status than serum folate), plasma methylmalonic acid (MMA — functional B12 status), plasma homocysteine (B12/folate/MTHFR functional marker), MTHFR C677T and A1298C genotyping, hsCRP and IL-6 (inflammatory hepcidin drivers), TSH and free T4 (hypothyroid macrocytic anemia), anti-TPO (autoimmune thyroid — common ACI driver), anti-tTG IgA with total IgA (celiac screen), and 25-OH vitamin D (vitamin D deficiency impairs erythropoiesis).
For patients in Southeast Michigan with unexplained fatigue, hair loss, brain fog, cold intolerance, or refractory anemia, Dr. Tom Biernacki and the team at The Private Practice offer comprehensive functional hematology evaluation to identify reversible root causes that routine blood work misses. Call (810) 206-1402 to schedule a consultation and get to the root cause of your blood health challenges.